When someone suffers an ischemic stroke, every moment counts. Doctors look for ways to improve outcomes and help patients regain their functions as quickly as possible. A recent review of 54 different studies looked at how a specific treatment, edaravone dexborneol, affects these results.
The analysis focused on patients with acute ischemic stroke. It found that those who received the treatment showed a significant reduction in NIHSS scores compared to those who did not. The NIHSS is a standard tool doctors use to measure the severity of a stroke and track how well a patient is recovering.
While the data shows a clear improvement in these early recovery scores, it is important to note that specific details regarding long-term outcomes at 90 days were not included in this summary. Additionally, the review did not provide specific information on side effects or safety risks. Because more detail is needed on long-term results and safety, you should talk to your doctor about how this treatment might fit into a specific care plan.
